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Tabebuia avellanedae Lorentz ex Griseb (family: Bignoniaceae) is distributed 
throughout the tropical rain forests of Central and South America. Its inner bark, commonly 
known as “taheebo”, “lapacho”,“pau d’arco”, and “ipe roxo”, is widely used in local and 
traditional phytomedicine for a long time. Colombians use the bark infusion the bark infusion 
as stimulant of central nervous system; Bahamians commonly use the bark decoction to 
prepare an energizing tonic for strength, and Brazilians use this plant to treat malaria, cancer, 
fever, stomach disorders, bacterial and fungal infections and to relief of a variety of mental 
and emotional states such as anxiety, poor memory, irritability and depression. 
Recent pharmacological study indicated that constituents of the bark of this plant exert a 
number of activities, such as anti-inflammation, anti-infectious, anti-cancer, antinociceptive, 
anti-emetogenic , anti-microbial, anti-fungal, anti-trypanosomal, anti-gastric lesions, 
anti-depressant, antiulcerogenic and anti-angiogenic. 
Following its popular use, the chemistry of this plant was extensively studied, and a 
variety of constituents have been isolated, such as furanonaphthoquinones, naphthoquinones, 
quinones, lignans, benzoic acid, cyclopentene dialdehyde, flavonoids, iridoids, phenolic 
glycosides, saponins, and coumarins. 
Aim: To find more bioactive natural product skeletons from the inner bark of Tabebuia 
avellanedae as leads to novel agents especially for the treatment of cancer and inflammatory in 
the future.  
Methods: Water extract and methanol extract of inner bark of Tabebuia avellanedae were 
separated, and the chemical structures and relative configurations of the new compounds were 
determined by 1D, 2D NMR and MS spectroscopic analyses. Cytotoxicity was evaluated by 
MTT assay on A549, SiHa and MCF-7 cells. Cell cycle analysis was evaluated by PI staining 
and apoptosis was determined by annnexin-V FITC/PI staining using flow cytometry analysis. 
Protein levels of cyclin protein family members was assessed by Western blotting and mRNA 
expressions of P53, BCL 2 and BAX were analyzed by RT-PCR. Inflammatory factors of NO, 
PGE2 and TNF- α were checked by ELISA on RAW 264.7 cells and the macrophages from BCG 
infected mouse.  
Results: 22 new compounds together with 10 known compounds were isolated and identified 
(in Fig. 1.). Among them, compound 30 and compound 31 inhibited the cell viability of all three 
cell lines; Results showed that compounds 29, 30 and 31 caused dose-dependent decreases in 
cell viability in all the cell lines; whereas the cells used in this study did not die significantly 
even at the highest concentration (13.5 μM) of compound 32. Furthermore, results indicated that 
the presence of a phenolic hydroxyl group at C-5 seems to play an important role in increasing 
anti-proliferative effect. Exposure of A549 to compound 30 and compound 31 resulted in 
significant increased distributions in the G2/M phase and S phase accompanied by a decreased 
distribution in the G1 phase time-dependently. The cell percentages of G2/M phase and S phase 
increased by 2.47-fold and 2.84-fold, respectively, after 48h treatment of compound 30, and 
increased by 3.33-fold and 1.86-fold, respectively, after 48h treatment of compound 31, while 
the cell percentage of G1 phase decreased by 3.31-fold after 48h treatment of compound 30 and 
decreased by 2.46-fold after 48h treatment of compound 31. The protein expression of cyclin A 
and cyclin B1 in A549 cells was significantly down-regulated after 24 h of exposure to 30 and 
31 and maintained at an extremely low level after 30 h of exposure to 30 and 31. In addition, 
decreased D1 protein level was also observed after 36 h of exposure. Compound 30 and 
compound 31 induced apoptosis in a time-dependent manner. The quantitative analysis showed 
the apoptosis rates (early and late) of compound 30 and compound 31 were 16.95% and 5.04% 
after 36h of treatment, and 22.81% and 26.60% after 48h of treatment, respectively. Compound 
30 and compound 31 induced rapid increases in P53 mRNA level from about 6-12 h after 
treatment, followed by apparent up-regulation of BAX at 36 h after treatment with no effect on 
BCL-2. Both compound 30 and compound 31 induced the activities of caspase-3 in a 
time-dependent way. LPS triggered macrophage activation and induced the rise in the 
production of inflammatory mediators of NO and PGE2, and all of the compounds exclude 
compound 1 can down-regulate the NO in a dose-dependent manner, while all of the 
compounds exclude compound 3 and 10 can down-regulate the PGE2 weakly, and 50μg/ml of 
compound 3 and 10 can down-regulate the PGE2 strongly. The concentrations of TNF-α were 
markedly increased after treatment with LPS in RAW 264.7 macrophages, but all these 
compounds used in this research had no effect on the TNF-α lever. In addition, all tested 
compounds showed no cytotoxic effects on RAW 264.7 macrophages. The anti-inflammatory 
properties of compounds were also investigated in LPS-activated macrophages from BCG 
infected mouse. We found that LPS triggered macrophage activation and induced the rise in the 
production of inflammatory mediators of NO and PGE2 and TNF-α. In the current investigation, 
all of the compounds exclude compound 1 can down-regulate the NO in a dose-dependent 
manner, and all of the compounds can down-regulate the PGE2 in a dose-dependent manner, 
but almost all these compounds used in this research had no effects on the TNF-α lever. The 
12.5μg/ml of compound 20 decreased the lever of TNF-α, but it seems to because of 
suppression of the cell viability. In addition, 50 μg/ml of 6, 8 and 13 showed cytotoxic effects 
on LPS-activated macrophages from BCG infected mouse. 
Conclusion: 22 new compounds together with 10 known compounds were isolated and 
identified (in Fig. 1.). Among them, compound 30 and compound 31 inhibited the cell viability 
of all three cell lines; compound 30 and compound 31 caused cell cycle arrest at G2/M and S 
phase and down-regulated cyclins A, B1, D1in a time dependent way; Compound 30 and 
compound 31 inducted apoptosis and up-regulated of P53 and BAX in a time dependent way. 
Furanonaphthoquinones (30 and 31) isolated from Tabebuia avellanedae are promising leads for 
potential anticancer drugs. Compounds 1, 3, 5, 6, 8, 9, 10, 11, 12, and 13 blocked the production 
of NO and PGE2 in a dose dependent way but not TNF-α without altering cell viability (except 
for high dose of 6, 8, 13 on mcrophages from mouse). Cyclopentenes and iridoids (1, 3, 5, 6, 8, 
9, 10, 11, 12, and 13) isolated from Tabebuia avellanedae may be the main constituents related 
to the anti-inflammatory effect of Tabebuia avellanedae.      
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Fig. 1. Anti-inflammatory and anti-cancer compounds from Tabebuia avellanedae. 
(■: New compounds ■: known compounds) 
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